Alcon Launches Tryptyr in the US for Rapid Relief of Dry Eye Disease

Alcon has officially announced the U.S. commercial launch of Tryptyr (acoltremon ophthalmic solution) 0.003%, following its FDA approval in May. Eye care professionals (ECPs) across the country can now prescribe Tryptyr to patients suffering from dry eye disease (DED). The therapy represents a first-in-class advancement in the treatment of DED, targeting both the signs and symptoms of this prevalent condition.

Overview of Tryptyr’s Mechanism of Action and Clinical Impact

Tryptyr is a TRPM8 receptor agonist, acting as a neuromodulator that stimulates corneal sensory nerves to rapidly boost natural tear production. Clinical trials demonstrated that Tryptyr produced a statistically significant increase in natural tear production as early as Day 1, providing a fast-acting solution for patients with dry eye symptoms.

“Tryptyr is highly anticipated in the dry eye disease treatment space as the first neuromodulator eye drop to rapidly increase natural tear production, as early as day one,” said Lisa Praeger, Vice President and General Manager of U.S. Ocular Health Pharmaceutical at Alcon.

Commercial Strategy and ECP Engagement

As part of the launch, Alcon is implementing a comprehensive education and engagement campaign for ECPs, which includes videos and digital tools, an interactive website tailored for professionals, a dedicated patient-facing website, and a national broadcast event featuring expert-led discussions on Tryptyr and its clinical application in dry eye disease.

These initiatives aim to inform and equip ECPs with resources to help integrate Tryptyr into their dry eye treatment protocols.

Access and Affordability Initiatives

To support broader patient access, Alcon has introduced a series of access-focused programs, including a ‘First Fill Free’ trial for eligible patients, ongoing copay support for refill prescriptions, and a field-based access management team dedicated to assisting providers with coverage and reimbursement logistics.

According to Alcon, these initiatives are designed to ensure that cost and coverage are not barriers to treatment, particularly during the initial stages of therapy.

“As the global eye care leader with a comprehensive portfolio of dry eye products—from over-the-counter offerings to prescription therapies—Alcon is uniquely positioned to deliver this innovation to ECPs and the millions of patients who need dry eye disease relief,” said Praeger.